{"id":"buntanetap-posiphen","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by targeting the translation initiation of APP and tau mRNA, thereby decreasing the levels of these neurotoxic proteins implicated in Alzheimer's disease pathology. By reducing both amyloid-beta and tau simultaneously, the compound addresses two hallmark pathologies of Alzheimer's disease. This dual mechanism is intended to slow cognitive decline in early symptomatic Alzheimer's disease.","oneSentence":"Buntanetap/posiphen inhibits translation of amyloid precursor protein (APP) and tau, reducing production of amyloid-beta and tau pathology in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:57.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"}]},"trialDetails":[{"nctId":"NCT07284784","phase":"PHASE2, PHASE3","title":"A Study of Buntanetap in Participants With PD","status":"RECRUITING","sponsor":"Annovis Bio Inc.","startDate":"2026-01-09","conditions":"Parkinson's Disease (PD), Deep Brain Stimulation","enrollment":500},{"nctId":"NCT06709014","phase":"PHASE3","title":"A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD","status":"RECRUITING","sponsor":"Annovis Bio Inc.","startDate":"2025-02-04","conditions":"Early Alzheimers Disease","enrollment":760},{"nctId":"NCT05686044","phase":"PHASE2, PHASE3","title":"A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD","status":"COMPLETED","sponsor":"Annovis Bio Inc.","startDate":"2023-04-01","conditions":"Alzheimer Disease","enrollment":351},{"nctId":"NCT05357989","phase":"PHASE3","title":"A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD","status":"COMPLETED","sponsor":"Annovis Bio Inc.","startDate":"2022-08-03","conditions":"Parkinson's Disease, Idiopathic","enrollment":523}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Posiphen Tartrate","ANVS401"],"phase":"phase_3","status":"active","brandName":"buntanetap/posiphen","genericName":"buntanetap/posiphen","companyName":"Annovis Bio Inc.","companyId":"annovis-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buntanetap/posiphen is a small molecule intervention being studied in clinical trials for conditions including early Alzheimer's disease, Alzheimer's disease, Parkinson's disease, and deep brain stimulation. Clinical trials are investigating the safety and efficacy of buntanetap/posiphen in these conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}